The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies
- PMID: 8558240
- PMCID: PMC6578795
- DOI: 10.1523/JNEUROSCI.16-03-01114.1996
The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies
Abstract
Nova-1, a protein expressed in tumors and neurons, is a target antigen in a human paraneoplastic motor disorder [paraneoplastic opsoclonus-myoclonus ataxia (POMA)]. We evaluated the relationship between the function of Nova-1 and its role as a disease antigen. We show that Nova-1 is a neuron-specific RNA-binding protein with sequence and functional similarities to FMR-1. Nova-1 mRNA is restricted to the subcortical nervous system, and the protein binds to RNA with high affinity. Nova-1 KH domains mediate this RNA binding, and point mutations within them abrogate binding. POMA disease antisera (6/6) recognize the third KH domain but not an inactive point mutant, and affinity-purified antibody blocks Nova-1 RNA binding. Thus, a cardinal feature of POMA is the production of antibodies that inhibit Nova-1-RNA interactions, suggesting such inhibition may cause the neurological disease.
Similar articles
-
The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia.Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13254-9. doi: 10.1073/pnas.95.22.13254. Proc Natl Acad Sci U S A. 1998. PMID: 9789075 Free PMC article.
-
Determination and augmentation of RNA sequence specificity of the Nova K-homology domains.Nucleic Acids Res. 2004 Sep 14;32(16):4852-61. doi: 10.1093/nar/gkh799. Print 2004. Nucleic Acids Res. 2004. PMID: 15367696 Free PMC article.
-
The neuronal RNA binding protein Nova-1 recognizes specific RNA targets in vitro and in vivo.Mol Cell Biol. 1997 Jun;17(6):3194-201. doi: 10.1128/MCB.17.6.3194. Mol Cell Biol. 1997. PMID: 9154818 Free PMC article.
-
Autoimmune central nervous system paraneoplastic disorders: mechanisms, diagnosis, and therapeutic options.Ann Neurol. 1995 May;37 Suppl 1:S102-13. doi: 10.1002/ana.410370711. Ann Neurol. 1995. PMID: 8968221 Review.
-
Immune diagnosis of paraneoplastic neurological disease.Clin Neurol Neurosurg. 1995 Feb;97(1):71-81. doi: 10.1016/0303-8467(95)00007-7. Clin Neurol Neurosurg. 1995. PMID: 7788979 Review.
Cited by
-
The neuron-specific RNA-binding protein ELAV regulates neuroglian alternative splicing in neurons and binds directly to its pre-mRNA.Genes Dev. 2001 Oct 1;15(19):2546-61. doi: 10.1101/gad.903101. Genes Dev. 2001. PMID: 11581160 Free PMC article.
-
The tetranucleotide UCAY directs the specific recognition of RNA by the Nova K-homology 3 domain.Proc Natl Acad Sci U S A. 2000 May 23;97(11):5740-5. doi: 10.1073/pnas.090553997. Proc Natl Acad Sci U S A. 2000. PMID: 10811881 Free PMC article.
-
NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer.Nat Commun. 2018 Aug 6;9(1):3112. doi: 10.1038/s41467-018-05582-x. Nat Commun. 2018. PMID: 30082712 Free PMC article.
-
The role of alternative pre-mRNA splicing in cancer progression.Cancer Cell Int. 2023 Oct 24;23(1):249. doi: 10.1186/s12935-023-03094-3. Cancer Cell Int. 2023. PMID: 37875914 Free PMC article. Review.
-
NOVA regulates Dcc alternative splicing during neuronal migration and axon guidance in the spinal cord.Elife. 2016 May 25;5:e14264. doi: 10.7554/eLife.14264. Elife. 2016. PMID: 27223328 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases